<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205828</url>
  </required_header>
  <id_info>
    <org_study_id>2009-268</org_study_id>
    <nct_id>NCT01205828</nct_id>
  </id_info>
  <brief_title>ABT-888 and Temozolomide for Liver Cancer</brief_title>
  <official_title>Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for people with liver cancer (also called hepatocellular carcinoma, or HCC in
      abbreviation).

      The purpose of this study is to test the efficacy (effectiveness) of a new combination of
      drugs, ABT-888 and temozolomide for patients with liver cancer. Temozolomide acts by damaging
      deoxyribonucleic acid (DNA) in rapidly dividing cells, in other words, cancer cells. ABT-888
      inhibits an enzyme called &quot;PARP&quot; which helps to fix damaged DNA. By inhibiting this enzyme,
      ABT-888 prevents cancer cells from repairing the damage caused by the temozolomide and will
      hopefully increase the killing of cancer cells, and decrease the tumors in the body.

      ABT-888 is an investigational or experimental anti-cancer agent that has not yet been
      approved by the Food and Drug Administration (FDA) for use in liver cancer.

      This study will help find out what effects (good and bad) the combination of drugs,
      temozolomide and ABT-888, has on liver cancer.

      This research is being done because it is not known if ABT-888 will increase the
      effectiveness of temozolomide in liver cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with hepatocellular carcinoma seen at Lombardi Cancer Center were evaluated for the
      eligibility of this study.

      The Georgetown Lombardi Comprehensive Cancer Center was responsible for the data and safety
      monitoring of this trial. As this study is an investigator initiated study Phase II study
      utilizing a non-FDA approved drug for which the PI held the IND it was considered a high risk
      study which had real-time monitoring by the PI and study team and quarterly reviews by the
      LCCC Data and Safety Monitoring Committee (DSMC).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>complete response at any time + partial response at any time + stable disease after 8 weeks of treatment based on RECIST Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>the number of months between a patient's enrollment and his/her date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The number of months between a patient's enrollment and his/her disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Grade 3 or 4 Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Record of all toxicities graded according to the NCI CTCAE version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Analysis</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate biological correlation with response to ABT-888 and temozolomide, including evaluation of loss of heterozygosity (LOH) of 13q, decreased expression of or mutations in BRCA-1 or -2, and a select assortment of DNA repair genes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Temozolomide and ABT-888 in HCC patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days</description>
    <arm_group_label>Temozolomide and ABT-888 in HCC patients</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-888</intervention_name>
    <description>ABT-888 40 mg BID PO Days 1-7 every 28 days</description>
    <arm_group_label>Temozolomide and ABT-888 in HCC patients</arm_group_label>
    <other_name>Veliparib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological confirmation of HCC or noninvasive criteria following AASLD guidelines

          -  Measurable or evaluable disease based on RECIST criteria

          -  Progressive disease on sorafenib or intolerance to sorafenib

          -  ECOG performance status 0-2

          -  Child Pugh Class A or B

          -  Adequate hepatic, bone marrow, and renal function

        Exclusion Criteria:

          -  Prior ABT-888 or other PARP inhibitor treatment

          -  Anticipation of need for major surgery during the study

          -  Any of the following within 6 months before enrollment: myocardial infarction,
             severe/unstable angina, congestive heart failure, or severe pulmonary disease

          -  Women who are pregnant or lactating

          -  Women and men of child-bearing potential who are not using a reliable form of
             contraception

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ABT-888 and temozolomide

          -  Concurrent malignancy (i.e. malignancy other than hepatocellular cancer) unless 1) the
             subject has been curatively treated and disease free for at least 2 years or 2) the
             cancer was non-melanoma skin cancer or early cervical cancer.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection (excluding active hepatitis B or C) or psychiatric illness/ social
             situations that would limit compliance with study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiwu R He, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2010</study_first_submitted>
  <study_first_submitted_qc>September 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <results_first_submitted>September 7, 2015</results_first_submitted>
  <results_first_submitted_qc>March 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2016</results_first_posted>
  <last_update_submitted>March 11, 2017</last_update_submitted>
  <last_update_submitted_qc>March 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Ruth He</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <keyword>hepatocellular</keyword>
  <keyword>temozolomide</keyword>
  <keyword>veliparib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ABT-888 and Temozolomide</title>
          <description>ABT-888 40 mg daily day 1-7/28 and temozolomide 150 mg/m2/day day 1-5/28</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16">Completed the first stage of the study, terminated as pre-planned due to lack of efficacy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temozolomide + ABT-888</title>
          <description>Temozolomide and ABT-888
temozolomide + ABT-888: Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
Patents with stable disease or continued response to therapy will be treated and followed for a total of 6 cycles (6 months).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="40" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Benefit Rate</title>
        <description>complete response at any time + partial response at any time + stable disease after 8 weeks of treatment based on RECIST Criteria</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABT-888 and Temozolomide</title>
            <description>ABT-888 40 mg daily day 1-7/28 and temozolomide 150 mg/m2/day day 1-5/28</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate</title>
          <description>complete response at any time + partial response at any time + stable disease after 8 weeks of treatment based on RECIST Criteria</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>the number of months between a patient's enrollment and his/her date of death</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABT-888 and Temozolomide</title>
            <description>ABT-888 40 mg daily day 1-7/28 and temozolomide 150 mg/m2/day day 1-5/28</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>the number of months between a patient's enrollment and his/her date of death</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="1" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>The number of months between a patient's enrollment and his/her disease progression</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABT-888 and Temozolomide</title>
            <description>ABT-888 40 mg daily day 1-7/28 and temozolomide 150 mg/m2/day day 1-5/28</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>The number of months between a patient's enrollment and his/her disease progression</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.8" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Grade 3 or 4 Adverse Events</title>
        <description>Record of all toxicities graded according to the NCI CTCAE version 3.0</description>
        <time_frame>6 months</time_frame>
        <population>grade 3 or 4 adverse events</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-888 and Temozolomide</title>
            <description>ABT-888 40 mg daily day 1-7/28 and temozolomide 150 mg/m2/day day 1-5/28</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Grade 3 or 4 Adverse Events</title>
          <description>Record of all toxicities graded according to the NCI CTCAE version 3.0</description>
          <population>grade 3 or 4 adverse events</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Analysis</title>
        <description>To evaluate biological correlation with response to ABT-888 and temozolomide, including evaluation of loss of heterozygosity (LOH) of 13q, decreased expression of or mutations in BRCA-1 or -2, and a select assortment of DNA repair genes.</description>
        <time_frame>6 months</time_frame>
        <population>Since the treatment showed no significant efficacy against HCC, therefore study of biomarker that predict responsiveness of the treatment was not carried out.</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide and ABT-888 in HCC Patients</title>
            <description>Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
Temozolomide: Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
ABT-888: ABT-888 40 mg BID PO Days 1-7 every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker Analysis</title>
          <description>To evaluate biological correlation with response to ABT-888 and temozolomide, including evaluation of loss of heterozygosity (LOH) of 13q, decreased expression of or mutations in BRCA-1 or -2, and a select assortment of DNA repair genes.</description>
          <population>Since the treatment showed no significant efficacy against HCC, therefore study of biomarker that predict responsiveness of the treatment was not carried out.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Temozolomide + ABT-888</title>
          <description>Temozolomide and ABT-888
temozolomide + ABT-888: Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
Patents with stable disease or continued response to therapy will be treated and followed for a total of 6 cycles (6 months).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea, vomit</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>bleeding</sub_title>
                <description>rupture of the primary tumor</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>multiorgan failure</sub_title>
                <description>hepato-renal syndrome from large quantity paracentesis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>platelet count decrease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>low neutrophil</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>low lymphocyte</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea, vomit</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Aiwu Ruth He</name_or_title>
      <organization>Georgetown University Medical Center</organization>
      <phone>202-444-8642</phone>
      <email>arh29@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

